New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →
Since the arrival of personalized healthcare and molecular diagnostics, there has been growing support for utilizing DNA, RNA, and protein-based biomarker detection methods as a means to help reduce rising healthcare costs (1). Molecular diagnostics can help select the right patients for the right treatments, and define which patients require costly confirmatory diagnostic tests. In… Read article →
Impressions from the QIAGEN booth at #ASHG2018 in San Diego. See you in Houston, TX in 2019! https://t.co/j3CQXsGK6E, Jennifer Poitras presents her poster at #ASHG2018 in San Diego on concordance of BRCA1/2 variant classification in… https://t.co/9nNN5M6I9q, Capture all relevant inherited mutations, including CNVs, SNVs, InDels and Fusions, for a range of rare hereditary… https://t.co/jqEeDtAhzP, Dr. Wenbo Xu, Lab Director at True Health Diagnostics, on the challenges faced in next generation sequencing when d… https://t.co/Zil7hj6cXy, Interested in gaining next-generation insights for hereditary disease? Visit the QIAGEN booth #1339 at #ASHG to lea… https://t.co/zhyXkZ7kDP, 
